Analyst Consensus ?
1 unmapped firm rating excluded from the percentages.
Stanley Black & Decker, Inc. · SWK · FY2026 Q1 · Calendar Q2 2026
Stanley Black & Decker's Q1 results show a company mid-transformation: revenue grew 3% year-over-year (flat organically) while adjusted EPS of $0.80 beat consensus of $0.59 by 35%, reflecting operating leverage from cost reductions and a roughly 4-point gross-margin improvement. The completed CAM aerospace fasteners divestiture generated $1.6B in net proceeds applied to debt reduction, supporting a target net debt-to-EBITDA of approximately 2.5x by year-end. Full-year 2026 guidance was maintained at adjusted EPS $4.90-$5.70 with approximately 150 bps of gross-margin expansion. Despite the beat, shares fell 3.1% on the report session before drifting 4.5% higher over the subsequent period.
Stanley Black & Decker, Inc. (SWK) is a global enterprise primarily engaged in two core business segments: Tools & Storage and Industrial operations. Its geographical footprint extends across the United States, Canada, the wider Americas region, France, the rest of Europe, and Asia. The Tools & Storage segment provides a comprehensive array of products catering to both professional and consumer markets. For professionals, offerings include high-grade corded and cordless electric power tools, essential equipment, pneumatic tools, and fastening solutions. Consumers can access corded and cordless electric power tools, notably under the BLACK+DECKER brand, alongside lawn and garden equipment, related accessories, various home products, hand tools, power tool accessories, and storage units. This division distributes its merchandise through a diverse network comprising retailers, distributors, and dealers, supplemented by a direct sales force.…
1 unmapped firm rating excluded from the percentages.
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jun 18, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | May 29, 2026 |
| JP Morgan | Underweight | Underweight | Maintain | May 1, 2026 |
| Baird | Neutral | Neutral | Maintain | Apr 21, 2026 |
| Barclays | Overweight | Overweight | Maintain | Apr 1, 2026 |
| Citigroup | Buy | Buy | Maintain | Feb 6, 2026 |
| UBS | Buy | Buy | Maintain | Jan 5, 2026 |
| Wolfe Research | Peer Perform | Underperform | Upgrade | Jul 8, 2025 |
| Mizuho | Outperform | Neutral | Upgrade | Dec 19, 2024 |
| Goldman Sachs | Neutral | Neutral | Maintain | Oct 10, 2024 |
| Zelman & Assoc | Buy | Hold | Upgrade | Aug 18, 2023 |
| Deutsche Bank | Hold | Hold | Maintain | Apr 12, 2023 |
| Credit Suisse | Neutral | Neutral | Maintain | Feb 6, 2023 |
| Longbow Research | Neutral | Buy | Downgrade | Feb 3, 2023 |
| Vertical Research | Hold | Buy | Downgrade | Jul 29, 2022 |
| B of A Securities | Underperform | Underperform | Maintain | Mar 9, 2022 |
| Gabelli & Co. | Buy | Hold | Upgrade | Jun 17, 2021 |
| Nomura Instinet | Buy | Buy | Maintain | May 4, 2020 |
| Nomura | Buy | Buy | Maintain | May 4, 2020 |
| Buckingham Research | Neutral | Neutral | Maintain | Jan 31, 2020 |
| Buckingham | Neutral | Neutral | Maintain | Jan 31, 2020 |
| Bank of America | Buy | Underperform | Upgrade | Nov 14, 2019 |
| Zelman | Hold | Buy | Downgrade | Oct 25, 2019 |
| Keybanc | Overweight | Downgrade | Sep 18, 2019 | |
| Macquarie | Outperform | Outperform | Maintain | Sep 6, 2018 |
| Argus | Hold | Buy | Downgrade | May 5, 2018 |
| MKM Partners | Buy | Buy | Maintain | Jan 25, 2018 |
| FBR Capital | Buy | Buy | Maintain | Oct 25, 2017 |
| Wunderlich Securities | Buy | Buy | Maintain | Oct 27, 2016 |
| Wunderlich | Buy | Buy | Maintain | Oct 27, 2016 |
| Susquehanna | Positive | Positive | Maintain | Apr 14, 2016 |
| Imperial Capital | In Line | In Line | Maintain | Jan 29, 2016 |
| Argus Research | Hold | Buy | Downgrade | May 30, 2013 |
| CLSA | Buy | Buy | Maintain | Feb 26, 2013 |
| Janney Capital | Neutral | Neutral | Maintain | Dec 20, 2012 |
| Raymond James | Market Perform | Outperform | Downgrade | Oct 18, 2012 |
Upside is calculated against the persisted previous close $95.55. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Goldman Sachs | Joe Ritchie | $93 | $93.05 | -2.7% | Jul 29, 2026 |
| Morgan Stanley | Christopher Snyder | $84 | $79.76 | -12.1% | May 28, 2026 |
| Robert W. Baird | Analyst unavailable | $84 | $75.89 | -12.1% | Apr 30, 2026 |
| Robert W. Baird | Timothy Wojs | $82 | $75.12 | -14.2% | Apr 21, 2026 |
| Morgan Stanley | Analyst unavailable | $87 | $87.29 | -8.9% | Feb 23, 2026 |
| Goldman Sachs | Joe Ritchie | $84 | $85.57 | -12.1% | Feb 5, 2026 |
| Barclays | Analyst unavailable | $100 | $84.63 | +4.7% | Feb 5, 2026 |
| Wells Fargo | Joseph O'Dea | $82 | $82.9 | -14.2% | Jan 14, 2026 |
| UBS | Analyst unavailable | $98 | $77.34 | +2.6% | Jan 5, 2026 |
| Robert W. Baird | Timothy Wojs | $85 | $75.24 | -11.0% | Dec 23, 2025 |
| Morgan Stanley | Analyst unavailable | $88 | $76.02 | -7.9% | Dec 22, 2025 |
| Morgan Stanley | Christopher Snyder | $80 | $65.38 | -16.3% | Oct 14, 2025 |
| Jefferies | Jonathan Matuszewski | $86 | $74.54 | -10.0% | Aug 18, 2025 |
| Goldman Sachs | Analyst unavailable | $80 | $67.77 | -16.3% | Jul 30, 2025 |
| Robert W. Baird | Timothy Wojs | $65 | $58.94 | -32.0% | May 1, 2025 |
| Wells Fargo | Joseph O'Dea | $60 | $58.94 | -37.2% | May 1, 2025 |
| Wells Fargo | Joseph O'Dea | $90 | $81.65 | -5.8% | Jan 7, 2025 |
| Goldman Sachs | Joe Ritchie | $94 | $93.87 | -1.6% | Oct 30, 2024 |
| Morgan Stanley | Jonathan Sakraida | $115 | $96.64 | +20.4% | Sep 10, 2024 |
| Morgan Stanley | Chris Snyder | $107 | $98.36 | +12.0% | Sep 6, 2024 |
| Robert W. Baird | Timothy Wojs | $94 | $106.05 | -1.6% | Jul 31, 2024 |
| Wells Fargo | Joseph O'Dea | $110 | $106.05 | +15.1% | Jul 31, 2024 |
| Robert W. Baird | Timothy Wojs | $80 | $86.95 | -16.3% | Jul 22, 2024 |
| Morgan Stanley | Julian Mitchell | $86 | $86.99 | -10.0% | Jun 4, 2024 |
| Barclays | Julian Mitchell | $107 | $95.46 | +12.0% | Apr 2, 2024 |
| Barclays | Julian Mitchell | $105 | $95.32 | +9.9% | Jan 31, 2024 |
| Morgan Stanley | Dan Oppenheim | $125 | $101.64 | +30.8% | Aug 15, 2022 |
| Wells Fargo | Joseph O'Dea | $105 | $97.33 | +9.9% | Aug 1, 2022 |
| Morgan Stanley | Joshua Pokrzywinski | $137 | $114.53 | +43.4% | Jun 6, 2022 |
| Morgan Stanley | Analyst unavailable | $150 | $126.44 | +57.0% | Apr 29, 2022 |
| Citigroup | Analyst unavailable | $110 | $125.83 | +15.1% | Apr 29, 2022 |
| Wells Fargo | Analyst unavailable | $158 | $127.78 | +65.4% | Apr 29, 2022 |
| Robert W. Baird | Timothy Wojs | $188 | $126.9 | +96.8% | Apr 29, 2022 |
| Credit Suisse | Daniel Oppenheim | $165 | $140.92 | +72.7% | Apr 10, 2022 |
| Barclays | Julian Mitchell | $180 | $141.6 | +88.4% | Apr 5, 2022 |
| Bank of America Securities | Ross Gilardi | $140 | $148.4 | +46.5% | Mar 16, 2022 |
| UBS | Markus Mittermaier | $248 | $173.47 | +159.5% | Feb 2, 2022 |
| Deutsche Bank | Nicole Deblase | $223 | $187.17 | +133.4% | Jan 10, 2022 |
| Wolfe Research | Nigel Coe | $246 | $192.86 | +157.5% | Jul 28, 2021 |
Track every rating change on SWK the moment it posts. Free to start.
Start freeFollow SWK with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeQ1 revenue rose 3% year-over-year versus a roughly 1% decline in Q4 2025, with adjusted EPS of $0.80 beating the $0.59 consensus estimate by 35%. Gross margin improved approximately 4 points, driven by productivity gains (~40%), fixed-cost restructuring (~40%), and tariff mitigation (~20%). The CAM Aerospace Fasteners divestiture to Howmet Aerospace closed at $1.8B gross proceeds, with $1.6B net applied to debt reduction, up from the $1.5B indicated last quarter. USMCA qualification is now ahead of pace, targeting less than 5% of U.S. sales from China-sourced products by year-end versus a prior target of the same threshold by end-2026. The board authorized up to $500M in share repurchases.
Maintained. Full-year 2026 guidance was unchanged: adjusted EPS $4.90-$5.70, flat revenue, low-single-digit organic growth, and gross-margin expansion of approximately 150 bps year-over-year. Capex outlook was not mentioned this quarter.
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.